IDYA
MaterialsIdeaya Biosciences Inc
Live · NASDAQ · May 9, Close
What's Moving IDYA Today?
No stock-specific AI insight has been generated for IDYA yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
IDYA News
21 articles- Assessing IDEAYA Biosciences (IDYA) Valuation After Positive Darovasertib Phase 2/3 Results And FDA Real-Time ReviewYahoo Finance·May 7, 2026
- IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 5, 2026
- IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 5, 2026
- Is IDEAYA Biosciences, Inc. (IDYA) A Good Stock To Buy Now?Yahoo Finance·May 3, 2026
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 1, 2026
- IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) ProgramYahoo Finance·Apr 30, 2026
- IDEAYA Biosciences, Inc. (IDYA) PT Increased as Wedbush Highlights Positive OptimUM-02 Trial ReadoutYahoo Finance·Apr 24, 2026
- IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal MelanomaYahoo Finance·Apr 21, 2026
- Novo teams with OpenAI; Ideaya gets muted response to eye drug dataBiopharmadive·Apr 14, 2026
- IDEAYA Biosciences Unveils OptimUM-02 Data: Darovasertib/Crizotinib Doubles PFS in Uveal MelanomaMarketbeat·Apr 14, 2026
- Ideaya Biosciences Surges On Promising Results For Hard-To-Treat MelanomaYahoo Finance·Apr 13, 2026
- Shares of This Cancer Therapy Maker Are Up 14%. Here’s Why.Yahoo Finance·Apr 13, 2026
- IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock SoarsBenzinga·Apr 13, 2026
- IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal MelanomaYahoo Finance·Apr 13, 2026
- IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026Yahoo Finance·Apr 10, 2026
- IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung CancerYahoo Finance·Apr 6, 2026
- Why IDEAYA Biosciences (IDYA) Is Up 7.5% After Early Data From First-in-Class Cancer ComboYahoo Finance·Apr 4, 2026
- A Look At IDEAYA Biosciences (IDYA) Valuation After New DLL3 Combo Trial Progress And Early ResponsesYahoo Finance·Apr 3, 2026
- Ideaya Biosciences Enrolls First Patient Evaluating Combination Therapy in Cancer TrialYahoo Finance·Mar 30, 2026
- IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and MelanomaYahoo Finance·Mar 30, 2026
- IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 TrialYahoo Finance·Mar 22, 2026
All 21 articles loaded
Price Data
Fundamentals
Trading
About Ideaya Biosciences Inc
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.